New 'liquid biopsy' blood test for breast cancer could help
A new type of blood test for breast cancer could help avoid thousands of unnecessary surgeries and otherwise precisely monitor disease progression, according to a study led by the Translational Genomics Research Institute (TGen) and Mayo Clinic in Arizona.

Published in the premier journal Science Translational Medicine, the study suggests that the test called TARDIS -- TARgeted DIgital Sequencing -- is as much as 100 times more sensitive than other blood-based cancer monitoring tests.

TARDIS is a "liquid biopsy" that specifically identifies and quantifies small fragments of cancer DNA circulating in the patient's bloodstream, known as circulating tumor DNA (ctDNA). According to the study, TARDIS detected ctDNA in as low as 2 parts per 100,000 in patient blood. TARDIS is precise enough to tell if early stage breast cancer patients have responded well to pre-operative drug therapy. It is more sensitive than the current method of determining response to drug therapy using imaging.

Unlike traditional biopsies, which only produce results from one place at one time, liquid biopsies use a simple blood draw, and so could safely be performed repeatedly, as often as needed, to detect a patient's disease status. The study results suggest that personalized ctDNA analysis, using TARDIS, is a promising approach to identifying patients with a curative response following pre-surgical drug therapy.

Patient samples for this study were collected at Mayo Clinic, at Addenbrookes Hospital at the University of Cambridge, and at City of Hope.

Source: https://pxmd.co/aEJDt
H●●●●m G●●●a and 38 others like this23 shares
Like
Comment
Share
Dr. N●●●●●●●a S●●h
Dr. N●●●●●●●a S●●h Obstetrics and Gynaecology
I would like more about this
Aug 8, 2019Like1
Dr. C●●●●n P●●●l
Dr. C●●●●n P●●●l Obstetrics and Gynaecology
Provide article if any
Aug 15, 2019Like
Dr. A●●Y K●●●R G●●G
Dr. A●●Y K●●●R G●●G Radiology
Sir, if the technic is in experiment stage or commercial available?
Aug 18, 2019Like